Product Description
Oxytetracycline is a bacteriostatic antibiotic. Newly discovered, additional mechanisms of action include antioxidant, antiinflammatory and immynosupresive activity of oxytetracycline and other tetracyclines. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17427500/)
Mechanisms of Action: Protein Synthesis Inhibitor,30S Ribosomal Subunit Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Austria | Bangladesh | Belgium | Brazil | Bulgaria | China | Colombia | Croatia | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Malaysia | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Slovenia | South Africa | Spain | Sweden | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Osteomyelitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PRESTO:Osteo | P1 |
Terminated |
Osteomyelitis |
2018-11-07 |